Yahoo Poland Wyszukiwanie w Internecie

Search results

  1. 15 wrz 2022 · Despite the many advances in cardiovascular medicine, decisions concerning the diagnosis, prevention, and treatment of left ventricular (LV) thrombus often remain challenging. There are only limite...

    • View EPUB

      PK u!3Yoa«, mimetypeapplication/epub+zipPK u!3Y...

    • Linda S. Williams

      Many diseases with specific indications for specific...

    • PDF/Epub

      PK u!3Yoa«, mimetypeapplication/epub+zipPK u!3Y...

    • Trial

      Background—The Randomized Evaluation of Long-term...

  2. Left ventricular (LV) thrombus is a feared complication of LV dysfunction associated with high rates of systemic embolism, morbidity, and mortality. Traditionally, LV thrombus has been associated with acute myocardial infarction (MI).

  3. Management of Patients at Risk for and With Left Ventricular Thrombus: A Scientific Statement From the American Heart Association.

  4. 23 wrz 2022 · On the basis of limited data, patients with nonischemic cardiomyopathy with LV thrombus should be treated with OAC for at least 36 months, with discontinuation if LV ejection fraction improves to >35% (assuming resolution of the LV thrombus) or if major bleeding occurs.

  5. Management of LV thrombus (LVT) is challenging and crucial to prevent the potential development of thromboembolic complications such as stroke. Anticoagulation with warfarin is recommended for the prevention of thromboembolic events, but novel oral anticoagulants (NOAC) have been used in clinical practice without supporting evidence.

  6. Left ventricular (LV) thrombus is a feared complication of LV dysfunction associated with high rates of systemic embolism. However, contemporary data are lacking. Methods. We identified patients diagnosed with LV thrombus on echocardiography (±contrast) at Brigham and Women's Hospital between January 2008 and May 2015. Results.

  7. 14 wrz 2022 · We suggest that, on the basis of limited data, patients with NICM with LV thrombus should be treated with OAC for at least 36 mo, with dis-continuation if LVEF improves to >35% (assuming resolution of the LV thrombus) or if major bleeding occurs.